Quick answers
- What is Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene hydrate) (2) used for?
- The FDA-approved label (Taclonex, LEO Pharma Inc., November 30, 2017) says: “Taclonex ® Topical Suspension is indicated for the topical treatment of plaque psoriasis of the scalp and body in patients 12 years and older. Taclonex Topical Suspension is a combination of calcipotriene, a vitamin D analog, and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis of the scalp and body in patients 12 years and older.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene hydrate) (2)?
- The “Adverse Reactions” section of the FDA label (Taclonex, LEO Pharma Inc., November 30, 2017) begins: “The most common adverse reactions (≥ 1%) are folliculitis and burning sensation of skin.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene hydrate) (2) have a boxed warning?
- No. None of the 1 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene hydrate) (2)?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
- Has Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene hydrate) (2) been recalled?
- FDA enforcement reports list 1 recall of products of this medicine; the newest started January 16, 2017 (Class III). A recall usually concerns specific lots, not every product.
- Who makes Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene hydrate) (2)?
- 1 company lists prescription products of Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene hydrate) (2) in the FDA NDC Directory, including LEO Pharma Inc.
What Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene hydrate) (2) is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Taclonex ® Topical Suspension is indicated for the topical treatment of plaque psoriasis of the scalp and body in patients 12 years and older. Taclonex Topical Suspension is a combination of calcipotriene, a vitamin D analog, and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis of the scalp and body in patients 12 years and older.
— FDA label: Taclonex, LEO Pharma Inc., effective November 30, 2017. Read the full label on DailyMed →
Label quoted: the one for the most common form (suspension, topical), Taclonex, LEO Pharma Inc.; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene hydrate) (2) side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
The most common adverse reactions (≥ 1%) are folliculitis and burning sensation of skin.
Read more of this section
(6.1) To report SUSPECTED ADVERSE REACTIONS, contact LEO Pharma Inc. at 1-877-494-4536 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Clinical Trials Conducted in Subjects 18 years and older with Psoriasis of the Scalp The rates of adverse reactions described below were from randomized, multicenter, vehicle- and/or active controlled clinical trials in adult subjects with psoriasis of the scalp [see Clinical Studies (14)]. Subjects applied study product once daily for 8 weeks, and the median weekly dose was 12.6 grams. Adverse reactions that occurred in ≥ 1% of subjects treated with Taclonex Topical Suspension and at a rate higher than in subjects treated with vehicle are presented in Table 1. Table 1. Number and Percentage of Subjects with Adverse Reactions in Scalp Psoriasis Trials (Events Reported by ≥1% of Subjects and for Which a Relationship is Possible) Taclonex Topical Suspension Betamethasone Dipropionate in vehicle Calcipotriene in vehicle Vehicle N=1,953 N=1,214 N=979 N=173 Event # of subjects (%) Folliculitis 16 (1%) 12 (1%) 5 (1%) 0 (0%) Burning sensation of skin 13 (1%) 10 (1%) 29 (3%) 0 (0%) Other less common adverse reactions (<1% but >0.1%) were, in decreasing order of incidence: acne, exacerbation of psoriasis, eye irritation, and pustular rash. In a 52-week trial, adverse reactions that were reported by >1% of subjects treated with Taclonex Topical Suspension were pruritus (3.6%), psoriasis (2.4%), erythema (2.1%), skin irritation (1.4%), and folliculitis (1.2%). Clinical Trials Conducted in Subjects 18 years and older with Psoriasis of the Body In randomized, multicenter, vehicle- and/or active controlled clinical trials in adult subjects with plaque psoriasis on non-scalp areas, 824 subjects applied Taclonex Topical Suspension once daily for 8 weeks [see Clinical Studies (14)]. The median weekly dose was 22.6 grams. There were no adverse reactions that occurred in ≥1% of subjects treated with Taclonex Topical Suspension and at a rate higher than in subjects treated with vehicle. Other less common adverse reactions (<1% but >0.1%) were, in decreasing order of incidence: rash and folliculitis. Clinical Trials Conducted in Subjects 12 to 17 years with Psoriasis of the Scalp In two uncontrolled clinical trials, 109 subjects aged 12 to 17 years with plaque psoriasis of the scalp applied Taclonex ® Topical Suspension once daily for up to 8 weeks. The median weekly dose was 40 grams.
Table from the label
| Taclonex Topical Suspension | Betamethasone Dipropionate in vehicle | Calcipotriene in vehicle | Vehicle | |
|---|---|---|---|---|
| N=1,953 | N=1,214 | N=979 | N=173 | |
| Event | # of subjects (%) | |||
| Folliculitis | 16 (1%) | 12 (1%) | 5 (1%) | 0 (0%) |
| Burning sensation of skin | 13 (1%) | 10 (1%) | 29 (3%) | 0 (0%) |
— FDA label: Taclonex, LEO Pharma Inc., effective November 30, 2017. This is part of the section. Read the full label on DailyMed →
Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene hydrate) (2) dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
Instruct patients to shake bottle prior to using Taclonex Topical Suspension. Apply Taclonex Topical Suspension to affected areas on the scalp and body once daily for up to 8 weeks. Taclonex Topical Suspension should be discontinued when control is achieved. Instruct patients to wash their hands after applying the product. Inform patients that they should not take a bath or shower or wash their hair right after application of Taclonex Topical Suspension.
Read more of this section
Patients 12 to 17 years should not use more than 60 grams per week and patients 18 years and older should not use more than 100 grams per week. Taclonex Topical Suspension should not be: Used with occlusive dressings unless directed by a healthcare provider. Used on the face, groin, or axillae, or if skin atrophy is present at the treatment site. Applied to the scalp in the 12 hours before or after any chemical treatments to the hair. Taclonex Topical Suspension is not for oral, ophthalmic, or intravaginal use. Shake bottle before use. (2) Apply Taclonex Topical Suspension to affected areas on the scalp and body once daily for up to 8 weeks. Discontinue therapy when control is achieved. (2) Patients age 12 to 17 years should not use more than 60 grams per week.(2) Adult patients should not use more than 100 grams per week. (2) Do not use with occlusive dressings unless directed by a healthcare provider. (2) Avoid use on the face, groin, or axillae, or if skin atrophy is present at the treatment site. (2) Not for oral, ophthalmic, or intravaginal use. (2)
— FDA label: Taclonex, LEO Pharma Inc., effective November 30, 2017. Read the full label on DailyMed →
Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene hydrate) (2) in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Risk Summary Available data with Taclonex Topical Suspension are not sufficient to evaluate a drug-associated risk for major birth defects, miscarriages, or adverse maternal or fetal outcomes. Although there are no available data on use of the calcipotriene component in pregnant women, systemic exposure to calcipotriene after topical administration of Taclonex Topical Suspension is likely to be low [see Clinical Pharmacology (12.3)].
Read more of this section
Observational studies suggest an increased risk of having low birth weight infants with the maternal use of potent or super potent topical corticosteroids (see Data). Advise pregnant women that Taclonex Topical Suspension may increase the potential risk of having a low birth weight infant and to use Taclonex Topical Suspension on the smallest area of skin and for the shortest duration possible. In animal reproduction studies, oral administration of calcipotriene to pregnant rats during the period of organogenesis resulted in an increased incidence of minor skeletal abnormalities, including enlarged fontanelles and extra ribs (see Data). Oral administration of calcipotriene to pregnant rabbits during the period of organogenesis had no apparent effects on embryo-fetal development. Subcutaneous administration of betamethasone dipropionate to pregnant rats and rabbits during the period of organogenesis resulted in fetal toxicity, including fetal deaths, reduced fetal weight, and fetal malformations (cleft palate and crooked or short tail) (see Data). The available data do not allow the calculation of relevant comparisons between the systemic exposures of calcipotriene and betamethasone dipropionate observed in animal studies to the systemic exposures that would be expected in humans after topical use of Taclonex Topical Suspension. The estimated background risk of major birth defects and miscarriage of the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Human Data Available observational studies in pregnant women did not identify a drug-associated risk of major birth defects, preterm delivery, or fetal mortality with the use of topical corticosteroids of any potency. However, when the dispensed amount of potent or super potent topical corticosteroids exceeded 300 grams during the entire pregnancy, maternal use was associated with an increased risk of low birth weight in infants. Animal Data Embryo-fetal development studies with calcipotriene were performed by the oral route in rats and rabbits. Pregnant rats received dosages of 0, 6, 18, or 54 mcg/kg/day (0, 36, 108, and 324 mcg/m 2 /day, respectively) on days 6-15 of gestation (the period of organogenesis). There were no apparent effects on maternal survival, behavior, or body weight gain, no effects on litter parameters, and no effects on the incidence of major malformations in fetuses.
— FDA label: Taclonex, LEO Pharma Inc., effective November 30, 2017. This is part of the section. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Suspension |
|---|---|
| Route | Topical |
| Prescription products | 1 in the FDA NDC Directory |
| Brand names | Taclonex |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| betamethasone dipropionate 0.05% · calcipotriene hydrate 50 ug/g suspension | Brand: Taclonex | $20.70 per gram |
NADAC list of November 11, 2026; these prices took effect on November 19, 2025. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- LEO Pharma Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA022185 TACLONEX | Leo Pharma As | May 9, 2008 | 15, latest July 25, 2019 2019: Efficacy · 2017: Manufacturing (CMC) · 2016: Manufacturing (CMC) |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
January 16, 2017 · Class III · Terminated · D-0477-2017
Labeling: Incorrect or missing package insert: the affected product was packaged with an out-of-date package insert (PI) dated February 2014.
Taclonex (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064%, packaged in (a) 60 g (NDC 50222-501-06), and (b)120 g (50222-501-66) tubes, Rx Only, Manufactured by: LEO Laboratories Ltd., 285 — LEO PHARMA INC
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 833461, 833463 |
|---|---|
| SPL set ID of the quoted label | 757c914f-dd8d-43cc-a973-212d591af4af |
| FDA labels (SPL) | 1 |
| FDA applications | NDA022185 |
| Active ingredients (FDA) | BETAMETHASONE DIPROPIONATE / CALCIPOTRIENE HYDRATE |
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- LEO Pharma Inc.Maker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Taclonex, LEO Pharma Inc., effective November 30, 2017; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →